Illumina: GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO

 

Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test

Galleri’s ability to detect more than 50 types of cancer with a single blood draw could transform early cancer detection as a complement to existing screenings; test now available in U.S. by prescription only

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today presented the first results from the interventional PATHFINDER study evaluating Galleri™, a multi-cancer early detection (MCED) blood test. The results, presented at the 2021 ASCO Annual Meeting, support Galleri’s performance in clinical settings. The company also announced today that Galleri is now available in the U.S. by prescription only.

"The interim results of PATHFINDER demonstrate that a routine blood test is capable of detecting many different cancers even before symptoms arise, an approach that has significant potential advantages," said Dr. Tomasz M. Beer, deputy director at the OHSU Knight Cancer Institute and presenting author. "Most importantly, it can detect cancers that have no recommended screening tests today, and more than two-thirds of cancers go unscreened for this reason. These results are a pivotal step toward extending early detection to many more types of cancer."

https://www.yahoo.com/now/grail-presents-interventional-pathfinder-study-110000124.html